HSK31858s efficacy results were comparable to previous brensocatib and BI 1291583 studies conducted in Europe and America, further validating DPP1 inhibition as an effective strategy for bronchiectasis treatment while providing important clinical evidence for Asian populations. The gene discussed is CTSC; the disease is bronchiectasis.